NORTHBROOK, Ill., May 21, 2014 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that twelve studies evaluating the performance and clinical impact of select Verigene® multiplex infectious disease tests have been presented at the 114th General Meeting of the American Society for Microbiology (asm2014), held this week in Boston, Massachusetts.
Help employers find you! Check out all the jobs and post your resume.
